Introduction
Augmented activation of peripheral chemoreceptors (PChRs) is a common feature in patients with systolic heart failure 1,2 associated with lower exercise capacity, greater arrhythmic burden, localized in the carotid bodies (CBs) may be responsible for disease progression. 5, 6 Both animal and clinical studies confirm a relationship between PChR afferent discharge and the level of sympathetic activity. Blockade of PChRs with hyperoxia in humans 7, 8 or resection of CBs in animals 5, 6 result in a significant decrease in sympathetic nerve traffic. Hyperactivity of the sympathetic nervous system is well defined in patients with heart failure, where it remains the priority target of both pharmacotherapy-and device-based interventions. 9 Thus, this has led to the novel concept that reducing afferent signalling of the CB may have therapeutic benefit in patients with systolic heart failure.
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Transient inhibition of PChRs with dopamine or oxygen has been shown to improve exercise capacity acutely. 11, 12 However, whether chronic desensitization of PChR translates into sustained improvements in exercise tolerance and hence better quality of life in the heart failure population is unknown.
Historically, the CBs have been surgically resected as a palliative therapy in patients with respiratory disorders in order to reduce or eliminate the respiratory drive of PChRs. 10, 13 Moreover, based on a vast number of published cases, both unilateral and bilateral surgical CB resection have been shown to be safe from the short-and long-term perspective. 10 However, CB resection itself carries some surgical risks related specifically to the operating field that include: inadvertent vessel and nerve damage, risk of central nervous system embolism, and persistent headache. Nonetheless, such complications have been described as rare, with an incidence rate of <3%. 10 Based on these premises, we tested the hypothesis that surgical CB resection in patients with systolic heart failure and augmented peripheral chemosensitivity could be safely performed and would result in a decrease in sympathetic tone and reduction in peripheral chemosensitivity. We previously presented a case report 14 and haemodynamic data obtained from the same cohort of patients.
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Methods
Study population
The study was performed in two stages. First, a group of four patients underwent unilateral CB removal (CBu). After reviewing all the cases in the context of safety, a second group of six patients was selected to undergo bilateral CB removal (CBb). The decision to move into bilateral procedures was based on the notion that more meaningful clinical changes may be obtainable with virtually complete elimination of PChR activity. This decision was made following interim safety and efficacy analysis of the data from the unilateral group.
Inclusion criteria for entering both stages were identical and included: stable heart failure symptoms in NYHA II-III class for at least 4 weeks prior to inclusion; LVEF ≤45%; optimized heart failure treatment; presence of both CBs in computer cervical angiotomography; and augmented peripheral chemosensitivity determined as >0.6 L/min/SpO 2 (cut-off based on previous findings from our lab and other reports). 1 -3 Exclusion criteria were as follows: acute coronary syndrome; coronary revascularization; heart failure-related hospitalization; clinically significant infection; surgery under general anaesthesia within 3 months prior to inclusion; history of stroke;
. 16, 17 None of the patients reported hospital admission due to heart failure decompensation within 1 year preceding the study, and seven patients reported history of heart failure hospitalization in the earlier period. We did not include NYHA IV patients as in this group the unstable course of the disease (together with the open design of the study) would complicate the evaluation of the effects of CB denervation.
The local Ethics Committee of Wroclaw Medical University approved the study protocol based on encouraging results of risk/benefit analysis taking into account low rates of the complications from >15 000 published cases of CB resection in humans and potential clinical benefit demonstrated in the animal models of heart failure and previous studies with chronic heart failure patients. 5 -8,10-12 The study protocol was identical to an already published case report 14 and for CBb patients presented in the haemodynamic context elsewhere. 15 All subjects gave written informed consent before study entry. The study was performed in accordance with the latest review of the Declaration of Helsinki. The protocols are registered with Clinical Trials for unilateral and bilateral procedures (NCT01653821 and NCT01782677).
Study endpoints
The primary outcome measures were defined as changes in: (i) muscle sympathetic nerve activity (MSNA) measured by burst frequency normalized to heart rate and (ii) peripheral chemosensitivity measured as ventilatory response to acute hypoxia at 1 month after CB resection. Secondary outcome measures included: changes in MSNA and peripheral chemosensitivity at 2 months after CB resection; changes in exercise tolerance and serum levels of natriuretic peptides at 1 and 2 months after CB resection; and change in LV function at 2 months after CB resection. Safety assessment comprised: analysis of procedural safety, arterial blood gas sampling, nocturnal oxygenation evaluated through 2 months post-procedure, and surveillance for adverse events for up to 12 months after CB resection. The study was designed as a proof-of-concept, safety, and feasibility trial; hence we decided on relatively short follow-up periods for primary and secondary endpoints. However, we also briefly report clinical data available at 6 months following CB resection.
Procedures
Peripheral chemosensitivity was measured using the standard transient hypoxia test employing brief administrations of nitrogen gas as described in more detail elsewhere. 2 Direct assessment of MSNA was achieved with multi-unit microneurography. Briefly, a tungsten microelectrode was inserted directly into the peroneal nerve posterior to the fibular head. The nerve signal was amplified and filtered (Neuro Amp Ex, ADInstruments, Sydney, Australia), which allowed for calculation of burst incidence per 100 heart beats as a measure of global sympathetic tone. 18 MSNA at baseline was performed in all subjects, but in one case was not repeated after CB resection due to the request of the patient. Despite not being a pre-specified endpoint, we decided to include heart rate variability (HRV) in our analysis. It was assessed using a spectral method. Low frequency (LF) (0.04-0.15 Hz) and high frequency (HF) (0.15-0.40 Hz) spectral bands were computed at rest in the supine position. The LF/HF ratio was used as an indirect measure of the sympathetic-parasympathetic balance. Such analysis was precluded in three patients due to frequent supraventricular arrhythmia or AF. Baroreflex control of MSNA was assessed with a baroreflex threshold method 19 using simultaneous MSNA and blood pressure recordings (Nexfin, BMEYE B.V., Amsterdam, The Netherlands).
Exercise capacity was assessed using treadmill spiroergometric test (modified Bruce protocol; Ultima, Medgraphics, St. Paul, MN, USA) and included calculation of peak oxygen consumption (peak VO 2 ), slope relating minute ventilation to carbon dioxide production (VE/VCO 2 slope), total exercise time, and respiratory exchange ratio (RER).
The study design is presented in detail in Table S1 in the Supplementary material online.
Carotid body resection
Carotid body resections were performed by a team of experienced vascular surgeons under local anaesthesia (2% lidocaine). Before surgery, the exact location of the CB and surrounding anatomy was assessed using cervical computed tomography (CT) angiography as described previously. 20 CB resection followed the method described earlier by Winter 13 which consists of a lateral approach to the carotid bifurcation with optional mobilization of the external carotid artery. Care was exercised to avoid damage to the vasculature and adjacent structures including: hypoglossal nerve, vagus nerve, thyroid artery, facial nerve, and carotid sinus baroreceptors. All unilateral procedures were performed on the right side for consistency. In every case, the surgeon was able to identify the CB macroscopically and resect it within the small block of adjusting tissues. The sample containing the CB was then put into formaldehyde, stained using the haematoxilin-eosin method, sectioned, and analysed for the presence of the CB by an experienced pathologist. A CB was defined as an easily discernible structure consisting of multiple glomoids containing chemosensitive cells (see Figure 1) .
Blood pressure, heart rate, respiratory rate, ECG, and oxygen saturation were monitored continuously during surgery and for 24 h after the procedure. In the group of patients receiving CBb resections, these were staggered in time (2-3 days apart). Patients were discharged from hospital on the third day following the second procedure. 
Data and statistical analysis
Statistica 10 (StatSoft Inc., Tulsa, OK, USA), LabChart Pro (ADInstruments) and MATLAB (MathWorks, Natick, MA, USA) were used to analyse the data. Variables were expressed as the mean and standard error of the mean (SEM) for repeated measurements before and after CB resection. In cases where repeated data were not available (e.g. death or refusal), a baseline value for that particular variable was not taken into account. Thus in some statistical comparisons <10 participants were taken into account (e.g. for statistical analysis of MSNA 9 cases were analysed at 1 month and 7 cases were analysed at 2 months). t-test for dependent samples and Wilcoxon matched pairs test were performed depending on the type of distribution (analysed with Shapiro-Wilk test) to assess differences in measured parameters after CB resection compared with baseline. A P-value <0.05 was considered statistically significant. Due to small sample size, statistical analysis was performed only in combined CBu and CBb groups.
Results
Study participants
Studied patients presented with moderate systolic heart failure as evidenced by decreased peak VO 2 (mean 16.2 mL/kg/min), compromised LV systolic function (mean LVEF 27.1%), and elevated NT-proBNP (mean 2337 pg/mL). They received optimal treatment-all were treated with a combination of ACE inhibitor/ARB with a beta-blocker (carvedilol at a mean daily dose of 43.75 ± 13.5 mg) and 9 (90%) had either an ICD or a CRT device implanted. Of importance, all patients demonstrated elevated MSNA ranging from 71 to 98 bursts/100 beats (in healthy volunteers of a similar age MSNA was reported as 64 ± 4 bursts/100 beats) 18 and presented with moderate risk of death within 3 years as per MAGICC score 21 (mean 27.6 ± 14.2%, range 12.2-55.6%). Baseline clinical characteristics of studied patients are shown in Table 1 .
Carotid body resection
Results of both CBu and CBb are presented in a case-by-case fashion in Table 2 and the Supplementary material online, Tables  S2-S4 . Tables S5 and S6 in the Supplementary material online show the results of CB resection according to group participation (CBu vs. CBb). A case report from one patient receiving CBu and data on haemodynamic response to hypoxia following CBb have been published elsewhere.
14,15 Histological examination confirmed completeness of surgical CB resection in all patients ( Figure 1 ).
Primary endpoints
Muscle sympathetic nerve activity at 1 month post-resection Nine patients underwent MSNA assessment at the 1-month visit. Compared with baseline, there was a significant decrease in burst frequency normalized to heart rate (86.6 ± 3.1 vs. 79.7 ± 4.2 bursts/100 min, P = 0.03) ( Figure 2 ). 
Peripheral chemosensitivity at 1 month post-resection
Carotid body resection (CBu + CBb) resulted in a significant decrease in peripheral chemosensitivity at the 1-month visit compared with baseline (1.35 ± 0.19 vs. 0.41 ± 0.17 L/min/SpO 2 , P = 0.005). Peripheral chemosensitivity was virtually eliminated in all patients receiving CBb (range 0.04-0.35 L/min/SpO 2 ), but did not reach levels regarded as normal (<0.6 L/min/SpO 2 ) in two of the four patients with CBu ( Table 2) .
Secondary endpoints Muscle sympathetic nerve activity at 2 months post-resection
Seven patients underwent MSNA assessment at the 2-month visit: two from the CBu group and five from the CBb group. There was a significant decrease in number of bursts normalized to heart rate compared with baseline (85.6 ± 3.9 vs. 75.4 ± 3.0 bursts/100 beats, P = 0.008) (Figure 2) . A numerical reduction in bursts/100 beats was seen in all patients studied at 2 months post-resection.
Peripheral chemosensitivity at 2 months post-resection
Carotid body resection (CBu + CBb) resulted in a significant decrease in peripheral chemosensitivity at the 2-month visit compared with baseline (1.40 ± 0.22 vs. 0.41 ± 0.14 L/min/SpO 2 , P = 0.006). Numerically PChRs were reduced in all patients with CBb (almost complete elimination relative to baseline) and in three of four patients with CBu (approximately half of the pre-procedural values) ( Figure 3 ; Table 2 ).
Exercise tolerance
All patients (CBu + CBb) exhibited significant prolongation of exercise time compared with baseline at 1 month (561 ± 58 vs. Table 2 ; Supplementary material online, Table S4 ).
Quality of life
The quality of life measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ clinical summary score) showed significant improvement (increase) at the 1-month visit compared with baseline (65.4 ± 5.5 vs. 76.1 ± 3.6, P = 0.005). However, the score at the 2-month visit did not differ significantly from the baseline (63.6 ± 5.4 vs. 69.4 ± 4.3, P = 0.12). Fatigue and shortness of breath scores (based on raw data extracted from KCCQ) showed improvement at every time point following CB resection. However, these changes reached statistical significance only for fatigue score at the 1-and 2-month visits. Details are given in the Supplementary material online, Table S7 .
Natriuretic peptides
There were no significant changes in NT-proBNP serum concentration at the 1-month (2337 ± 719 vs. 2596 ± 834 pg/mL, P = 0.24) or the 2-month visits (2536 ± 895 vs. 2652 ± 1042 pg/mL, P = 0.89) compared with baseline.
Left ventricular function
Left ventricular ejection fraction did not change significantly at 2 months relative to baseline (28.5 ± 2.6 vs. 29.6 ± 2.9%, P = 0.39). Similarly, there was no significant difference in LV end-diastolic diameter (70.0 ± 5.4 vs. 71.5 ± 5.2 mm, P = 0.13).
Heart rate variability
The LF/HF ratio did not change at 1 month (1.00 ± 0.13 vs. 0.73 ± 0.12, P = 0.24) when compared with baseline. However, there was a significant decrease in the LF/HF ratio at the 2-month visit (1.04 ± 0.15 vs. 0.48 ± 0.1, P = 0.028). At 2 months, the LF/HF ratio was found to be reduced in all patients with available data (n = 6) when compared with baseline.
Safety assessment Peri-procedural safety
There were no acute changes in blood pressure, heart rate, oxygen saturation (SpO 2 ), respiratory rate, and ECG immediately after either bilateral or unilateral CB resection(s) and during 24 h of post-procedural continuous monitoring. There was one inadvertent arterial puncture during the surgery which was promptly repaired by the operating surgeon without any long-term consequences. In two patients, we noted ipsilateral damage to the facial nerve which tended to resolve without intervention within the follow-up period. One participant complained of headache and jaw numbness which gradually improved during the follow-up.
Oxygenation at night
One patient from the CBb group with pre-existing moderate obstructive sleep apnoea exhibited significant prolongation and deepening of apnoeic episodes, and the minimal SpO 2 value decreased from 79% at baseline to 49% at 2 months. This was successfully addressed with the prescription of an adaptive servoventilation device. In two other patients with CBb, we noted less pronounced changes in minimal SpO 2 at night (from 82% at baseline to 72% at 2 months and from 83% at baseline to 73% at 2 months) without the need for clinical intervention. In one patient from the CBu group we found a reduction in minimal SpO 2 level at night from 88% to 78%. There were no significant changes in minimal SpO 2 levels at night in the remaining patients. See Supplementary material online, Table S8 for detailed results.
Arterial blood gas analysis
There were no significant changes in the oxygen arterial partial pressure (PaO 2 ) at 1 month (74.5 ± 1.9 vs. 73.9 ± 2.8 mmHg, P = 0.96) or 2 months post-resection relative to baseline (75.8 ± 2.2 vs. 75.0 ± 3.7 mmHg, P = 0.78). The lowest PaO 2 level noted at either the 1-or 2-month visits was 57 mmHg.
Concomitantly, we observed an increase in carbon dioxide arterial partial pressure (PaCO 2 ) in five patients at 1 month (all from the CBb group) and in five patients at 2 months (1 with CBu and 4 with CBb) compared with baseline. These changes reached statistical significance at 2 months after CB resection (36.9 ± 0.9 vs. 39.5 ± 1.0 mmHg, P = 0.07 at 1 month and 37.5 ± 0.8 vs. 40.3 ± 1.3, Table S2 ).
Serious adverse events
Two deaths occurred during the 12-month follow-up period.
One patient from the CBb group with a history of ventricular arrhythmias and adequate ICD interventions died at night 55 days after CB resection due to multiple episodes of ventricular tachycardia and ventricular fibrillation.
One patient from the CBu group with severe dilated cardiomyopathy died 8 months after the study intervention. This event occurred suddenly during the day-time and its cause remains unclear. Post-mortem examination was not carried out. Additional details on two deaths are provided in the Supplementary material online, Table S9 .
There was also one hospitalization due to decompensated heart failure which took place 11 months after CBb. ability to recognize symptoms of worsening heart failure was not distorted by the lack of hypoxic sensing.
Blood pressure, heart rate, and arrhythmic burden
There were no significant changes in mean office blood pressure either 1 or 2 months post-CB resection (82.5 ± 3.7 vs. 85.3 ± 3.2 mmHg, P = 0.19 and 85.2 ± 4.1 vs. 84.6 ± 3.0 mmHg, P = 0.91, respectively) (Supplementary material online, Table S3 ). We did not observe any signs of baroreceptor dysfunction following CB resection such as fluctuation in clinical blood pressure measurements or orthostatic hypotension as reported by study participants. Data on baroreflex control of MSNA are provided in the Supplementary material online, Table S10 . Similarly, we found no significant change in mean 24 h heart rate at 2 months post-CB removal compared with baseline (81.6 ± 2.1 vs. 81.0 ± 2.5 b.p.m., P = 0.82) (Supplementary material online, Table S3 ). 
Clinical data at 6 months following carotid body resection
We found the following significant changes at the 6-month visit relative to baseline: (i) decrease in peripheral chemosensitivity (P = 0.009); (ii) decrease in the LF/HF ratio (P = 0.04); (iii) increase in exercise time (P = 0.03); (iv) increase in PaCO 2 (P = 0.049); (v) increase in serum creatinine (P = 0.046); and (vi) decrease in office heart rate (P = 0.046). See Supplementary material online, Table S11 for details. Described changes in serum creatinine and office heart rate were not seen at the 1-month and 2-month visits.
Discussion
To our knowledge, this is the first human study showing a decrease in sympathetic tone following CB resection. We studied patients with moderate heart failure who demonstrated augmented peripheral chemosensitivity and elevated MSNA (direct and reproducible measurement of efferent sympathetic traffic) despite optimal pharmacological and device therapy. This is of particular importance as exaggerated sympathetic tone and high activity of PChRs are related to increased mortality in systolic heart failure. 4, 22, 23 By blocking PChRs with transient hyperoxia, Despas et al. showed a decrease in MSNA in heart failure patients. 8 Similar results were obtained from patients with hypertension. 24 Recent data from a rat and rabbit model of systolic heart failure further support this concept. Del Rio et translated into improved barosensitivity, augmented LV function, reduced cardiac arrhythmias, and better survival. 5 Similar results were obtained by Marcus et al. 6 It has been established that afferent discharge from PChRs impinges on neurons in the nucleus of the tractus solitarii that relay to activate sympathetic neurons in various regions of the central nervous system (e.g. paraventricular nucleus, rostral ventrolateral medulla oblongata). 25 This in turn results in augmentation of sympathetic post-ganglionic activity. 26 Thus, bilateral resection of CB resulting in eradication of afferent signalling to these structures is most probably responsible for the reduction in MSNA seen in the current study. Another possible explanation involves a decrease in the central coupling between respiratory and sympathetic neural networks 27 related to diminished ventilatory response to hypoxia after bilateral CB resection; this, however, was not directly assessed in our study. While numerically, the decline in MSNA might seem small (10 bursts/100 beats at 2 months), it must be noted that it equates to ∼45% of the excess sympathetic activity related to the heart failure state (when compared with healthy volunteers of similar age).
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In the present study, we also describe an improvement in exercise capacity. This manifested as longer exercise times in all subjects (CBu and CBb). At the same time, we noted a decrease in the VE/VCO 2 slope in all CBb patients 2 months post-operatively, reflecting enhanced efficiency of ventilation during exercise-possibly as a result of attenuation in hypercapnic ventilatory response. Experimental studies involving acute PChR blockade showed similar results. Chua et al. using hyperoxia to block PChRs in heart failure subjects described prolongation of exercise time.
12 Furthermore, Notarius et al. reported improved exercise time in heart failure patients following caffeine administration 28 (a known chemoreflex attenuator 29 ). In another study employing dopamine to inhibit PChRs in healthy volunteers, a decrease in the VE/VCO 2 slope was also reported.
11 The beneficial effect of CB resection on exercise capacity might be related to the attenuation of sympathetic constraint towards skeletal muscle arterioles as described in a heart failure animal model. 30 On the other hand, it could be hypothesized that exercise improvements might be related to the subjective perception of reduced dyspnoea, which has been demonstrated after CB resection for other respiratory disorders 31 and following oxygen administration in heart failure. 32 Also, because of the lack of a sham control group, we cannot rule out the placebo effect in relation to the improvements seen in exercise capacity.
There was no significant change in NT-proBNP levels following CB intervention. While on the one hand this could point towards futility of the described intervention, on the other hand it suggests that a decrease in sympathetic activity and improvement in exercise time may well be independent of myocardial performance. 33 During available follow-up, we observed no significant changes in LV function and morphology. This observation is consistent with the lack of improvement in NT-proBNP levels. Thus, it could be speculated that augmented MSNA seen commonly in heart failure patients has predominantly a secondary role and its involvement in further progression of the disease is over-rated-at least in a case of long-standing and advanced systolic heart failure.
As expected from previous observations carried out on individuals after CB removal, 34 we observed an increase in PaCO 2 levels, which was more notable in the CBb group. This effect might have been mediated by a reduction in resting ventilation caused by a loss of excitatory input from the CB to the central chemoreceptors. 35 Yet, this was not directly evaluated in this study. A similar effect together with reduced chemoreflex CO 2 sensitivity was observed in rabbits with chronic heart failure following CB ablation. 6 While being relatively small (of ∼3-4 mmHg), the rise in PaCO 2 could be of some clinical significance. As demonstrated by Lorenzi-Filho et al., 36 even such a degree of increase in PaCO 2 may alleviate central sleep apnoeas and hypopnoeas. Because our population of CBb patients consisted of individuals with an obstructive pattern of sleep-disordered breathing, this effect could not be seen.
In all subjects 1 month after CB resection, quality of life measured with the KCCQ improved. It could be related to less perception of dyspnoea and better exercise tolerance after CB removal. In fact, our analysis of raw data obtained with the KCCQ showed a degree of improvement in both fatigue and shortness of breath scores. However, a short-lived 'placebo' effect related to the surgical procedure is a possibility supported by less obvious improvements in quality of life seen at 2 and 6 months. At the same time, the latter could reflect the ongoing adaptation to diminished ventilatory drive. Whether the observed improvements in quality of life are related to a reduced subjective sensation of dyspnoea or to primarily enhanced exercise capacity cannot be conclusively derived from our findings.
In some patients, CB resection resulted in the reduction of the minimal level of SpO 2 at night. This was mostly seen in the CBb group and had serious clinical consequences in one patient who required intervention with non-invasive ventilation. Such an effect is most probably related to the elimination of PaO 2 sensing which is mainly provided by the chemoreceptors in the CBs. Central sensors predominantly detecting changes in PaCO 2 are delayed in the relationship to the CBs, therefore resulting in longer apnoeas and hypopnoeas, leading to deeper desaturations after bilateral CB removal. Conversely, unilateral CB removal has a less significant effect on sleep-disordered breathing probably because of the preservation of hypoxic sensing by the contralateral CB. Exacerbated apnoeas/hypopnoeas in the CBb group may also be related to reduced central CO 2 chemosensitivity as discussed above. 6 Despite the mitigation of 45% of sympathetic excess in heart failure patients included in our study, we did not see a significant impact on blood pressure. This can be explained by low baseline blood pressure due to low cardiac output and up-titrated pharmacotherapy. We also did not see a meaningful change in heart rate at 2 months. However at 6 months we noted a small (6 b.p.m.) but statistically significant decrease in office heart rate measurements. Changes in heart rate might have been blunted by the presence of atrial arrhythmia in 3 out of 10 study participants.
The authors cannot rule out the relationship between CB resection and two deaths that occurred during follow-up. However, such a relationship seems rather unlikely. Table S9 for details). Currently tested devices used for neuromodulation in heart failure (baroreceptor stimulation and vagal nerve stimulation) may be associated with poorly tolerated side effects occurring during the therapy which may limit the efficacy of such modalities. 37, 38 In contrast, CB denervation is free from the ongoing sensation related to continuous electrical stimulation. However, as seen in this study, CB denervation is a definitive procedure with the possibility of side effects related to the operative field. To avoid the risks related to the surgical approach, a transvascular method of CB ablation might be an interesting option.
Moving forward into future clinical trials requires careful consideration of potential safety issues and should rather focus on unilateral procedures (which showed some positive efficacy signals in the current study, see Supplementary material online, Tables S5 and S6) with exclusion of patients with pre-existing obstructive sleep-disordered breathing. Also, it is not clear at which stage of the natural course of systolic heart failure sympathetic modulation by means of CB resection should be tested.
Our study is not without limitations. Because of the surgical nature of the CB removal, we did not include a control group with sham procedures or a control group of 'matched' heart failure patients receiving standard treatment. Nonetheless, we believe that the relatively short follow-up period makes changes related to the progression of heart failure less likely. We present MSNA data only for 1-month and 2-month visits, which is consistent with pre-defined study endpoints. However, long-standing reduction in sympathetic tone is confirmed by HRV analysis available for 6 months of follow-up. We did not include female participants, which could influence some of the results (e.g. oxygenation at night due to lower prevalence of sleep-disordered breathing in women). Finally, we acknowledge missing data (two drop-outs) related to death and a patient's wish to terminate study participation due to personal reasons and the subjectively demanding study protocol.
In conclusion, CB resection constitutes an interesting novel approach to sympathetic modulation in heart failure. Our first-in-man data report a decrease in MSNA and improvement in some indices of exercise capacity with concomitant reduction in peripheral chemosensitivity. Bilateral CB resection may result in clinical worsening of nocturnal hypoxaemia, while unilateral CB resection appears to have little effect on oxygenation at night. Careful consideration of the balance between safety issues related to invasiveness and definitiveness of the procedure and somewhat limited clinical efficacy is necessary before further clinical trials.
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